| Autor: |
Rusu A; Department of Morpho-Functional Sciences I-Histology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania., Caruntu ID; Department of Morpho-Functional Sciences I-Histology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania.; Department of Pathology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania., Lozneanu L; Department of Morpho-Functional Sciences I-Histology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania.; Department of Pathology, 'Sf. Spiridon' Clinical Emergency County Hospital, 700111 Iasi, Romania., Ciobanu DG; Department of Pathology, 'Sf. Spiridon' Clinical Emergency County Hospital, 700111 Iasi, Romania.; Department of Morpho-Functional Sciences I-Morphopathology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania., Amalinei C; Department of Morpho-Functional Sciences I-Histology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania., Giusca SE; Department of Pathology, 'Dr. C.I. Parhon' Clinical Hospital, 700503 Iasi, Romania.; Department of Morpho-Functional Sciences I-Morphopathology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania. |
| Abstrakt: |
Pancreatic ductal adenocarcinoma (PDAC) represents the most frequent pancreatic malignancy, with stromal and epithelial heterogeneity reflected in outcome variability. Therefore, a molecular classification is promoted based on the validation of new diagnostic and prognostic markers. Galectin-8 (Gal8) has been pointed out as a prognostic factor for survival in several types of tumors. Due to limited existing data on PDAC, our study aimed to evaluate the Gal8 profile in PDAC alongside its prognostic status. A total of 87 cases of PDAC were immunohistochemically investigated, and Gal8 immunoexpression was qualitatively and semi-quantitatively assessed and correlated with classical clinicopathological parameters and survival. Gal8 immunoexpression was identified to be mostly nuclear and cytoplasmic, followed by exclusively cytoplasmic and exclusively nuclear. A statistical analysis between Gal8 profiles defined by negative, low, or high scores and clinicopathological characteristics showed significant differences in tumor size, pN stage, and lympho-vascular invasion. Although a Cox regression analysis did not support the prognostic status of Gal8, and we did not confirm its relationship with OS, our results show that exclusively nuclear labeling was associated with an increased mean OS compared with cytoplasmic and nuclear labeling (29.37 vs. 17.93 months). To the best of our knowledge, this is the first study to report a detailed pattern of Gal8 immunostaining in PDAC and to correlate this pattern with clinicopathological characteristics and survival. Our results show that Gal8 immunoexpression is associated with a more aggressive phenotype, thus opening perspectives for larger studies to validate Gal8 as a prognostic factor. |
